Lawrence M. Sung

Lawrence is a registered patent attorney with a Ph.D. in microbiology who has over 20 years of experience in biotechnology, medical device, and pharmaceutical (small molecule and biologics) patent counseling, litigation, and technology transfer. Having served on several professional school faculties, he is also a recognized intellectual property law scholar.

Representative Experience

• Represented Abbreviated New Drug Applicant for generic Abilify® (aripiprazole) in Hatch-Waxman litigation before the U.S. District Court for the District of New Jersey.
• Represented, as lead counsel, a global medical technology company in an amicus curiae submission before the Supreme Court of the United States in Teva Pharms. USA, Inc. v. Sandoz, Inc.
• Represented Abbreviated New Drug Applicant for generic Toviaz® (fesoterodine fumarate) in Hatch-Waxman litigation before the U.S. District Court for the District of Delaware.
• Represented Abbreviated New Drug Applicant for generic Treanda® (bendamustine hydrochloride) in Hatch-Waxman litigation before the U.S. District Court for the District of Delaware.
• Conducted an intellectual property due diligence investigation involving drug therapies for cancer and inflammatory disorders for a biopharmaceutical company client resulting in a successful $925 million acquisition.
• Represented, as lead counsel, a global medical technology company in an amicus curiae submission before the U.S. Supreme Court in Bilski v. Kappos.

Professional Experience

• Professor, John Hopkins University Carey Business School (2013-Present)
• Lecturer, Catholic University of American Columbus School of Law (2013-Present)
• Professor and Intellectual Property Law Program Director, University of Maryland School of Law (2001-2012)
• Former Consultant, National Institutes of Health, National Human Genome Research Institute

Affiliations

• American Bar Association, Section of Intellectual Property Law (ABA-IPL)
• American Intellectual Property Law Association (AIPLA)
• Asian-Pacific American Bar Association of the District of Columbia
  • Past Chair, Partners’ Forum
• The National Research Council
  • Past Chair, Committee on Intellectual Property Concerns for Toxicogenomics
  • Former Member, Committee on Validation of Toxicogenomics Technologies
• Former Member, The National Academies Standing Committee on Emerging Issues and Data on Environmental Contaminants
• Former Patent Peer Review Committee Member, The Biojudiciary Project: A Jurist’s Guide to 21st Century Biotechnology

Recognitions

• Named one of DC's "Super Lawyers" for Intellectual Property Litigation by Super Lawyers magazine (2018)

• Included in The Best Lawyers in America directory for Biotechnology Law (2013-2018) and named “Lawyer of the Year” for Biotechnology Law in Washington, DC (2016)